Capricor Therapeutics, Inc. announced that on January 20, 2014, the employment of Anthony Davies as the company's Chief Technology Officer was terminated by mutual agreement of the company and Mr. Davies, effective immediately.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.955 USD | -1.89% | -3.87% | +21.88% |
05-17 | Oppenheimer Initiates Capricor Therapeutics at Outperform Rating | MT |
05-13 | Transcript : Capricor Therapeutics, Inc., Q1 2024 Earnings Call, May 13, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+21.88% | 191M | |
+12.23% | 116B | |
+12.76% | 106B | |
-9.35% | 23.89B | |
-1.69% | 21.58B | |
-10.60% | 18.96B | |
-41.25% | 16.96B | |
-15.45% | 16.33B | |
+6.24% | 14.14B | |
+29.86% | 12.02B |
- Stock Market
- Equities
- CAPR Stock
- News Capricor Therapeutics, Inc.
- Capricor Therapeutics, Inc. Announces Termination of Employment of Anthony Davies as Chief Technology Officer